Disclosed are MC-3/MC-4 receptor ligands, the ligands having the following
formula:
##STR1##
wherein A is a conformationally restricted ring system selected from the
group consisting of:
a) non-aromatic carbocyclic rings;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
wherein said rings comprises from 5 to 8 atoms; and W is a unit which preferable
comprises D-1-fluorophenyalanine, Y comprises a heteroatom, and Z comprises an
aromatic carbocyclic ring. Also disclosed are pharmaceutical compositions comprising
the ligands of the invention as well as methods of treating diseases mediated through
MC-3/MC-4 receptors.
